This article explores the development of T cell-based therapies in Switzerland. These therapies, which elicit the immunological potential of each patient to respond to tumor development, constitute a major promise for so-called ‘precision oncology’. We document how immunological concepts, technologies, and practices are articulated given the centrality of genomics in ‘precision oncology’. We consider ‘precision immunotherapies’ to probe whether and how change ensues in these established sociotechnical regimes of biomedicine. The case of genomics and immunology in oncology offers a unique insight into the conditions of possibility for change in such regimes. How does the present new wave of cancer immunotherapies challenge, integrate, and complement the centrality of genomics in ‘precision oncology’? What are the specific processes that make possible the convergence, competition, or co-existence of distinct conceptions, infrastructures, and programs of innovative cancer medicine? Drawing from observations and interviews with researchers and clinicians, we qualify these sociotechnical processes as hybridizations. Bringing together different sociotechnical regimes of biomedical research is conditional to the articulation of core concepts, technologies, and translational practices of genomics and immunology. Pivotal to this objective are neoantigens, cell surface proteins originating from the somatic genetic mutations of tumors and which activate a patient’s immune response. While neoantigens are an unstable entity in experimentation, they offer a conceptual and material substrate to renegotiate the dominance of cancer genomics, and initiate the production of a new, hybrid regime of ‘immunogenomic precision’ in oncology.

中文翻译：

---

精准的免疫肿瘤学转向？通过基于新抗原的过继细胞疗法实现癌症基因组学和免疫疗法的杂交


本文探讨了瑞士基于 T 细胞的疗法的发展。这些疗法激发了每位患者对肿瘤发展做出反应的免疫潜力，构成了所谓的“精准肿瘤学”的主要前景。鉴于基因组学在“精准肿瘤学”中的核心地位，我们记录了免疫学概念、技术和实践是如何阐明的。我们考虑“精准免疫疗法”来探索这些已建立的生物医学社会技术制度是否以及如何随之变化。肿瘤学中的基因组学和免疫学案例为这种制度中可能发生变化的条件提供了独特的见解。当前新一波癌症免疫疗法如何挑战、整合和补充基因组学在“精准肿瘤学”中的中心地位？使创新癌症医学的不同概念、基础设施和项目之间的融合、竞争或共存的具体过程是什么？根据对研究人员和临床医生的观察和访谈，我们将这些社会技术过程定性为杂交。将生物医学研究的不同社会技术制度汇集在一起，以阐明基因组学和免疫学的核心概念、技术和转化实践为条件。实现这一目标的关键是新抗原，即源自肿瘤体细胞基因突变的细胞表面蛋白，可激活患者的免疫反应。虽然新抗原在实验中是一种不稳定的实体，但它们为重新协商癌症基因组学的主导地位提供了概念和材料基础，并在肿瘤学中启动了一种新的混合机制的“免疫基因组学精确性”。